Syndicated Research Studies

How large can a drug class get once it proves it can treat obesity, diabetes and heart risk at the same time? The peptide therapeutics market offers an early answer. Valued at USD 140.9 billion in 2025, it is projected to reach USD 294.6 billion by 2033, growing at 8.7% annually from 2026. North America accounts for 61.9% of today’s revenue, but the factors that decide the next USD 130 billion, such as manufacturing capacity, oral delivery and generic competition, are only now taking shape. Market Size and Forecast: What the Numbers Say The peptide therapeutics market adds roughly USD 130.6 billion in revenue between 2026 and 2033 (USD 294.6 billion minus USD 164.0 billion), an increase of about 80% in seven years. One detail is easy to miss. The move from USD 140.9 billion in 2025 to USD 164.0 billion in 2026 is about 16.4%, nearly double the forecast CAGR. This is our own calculation from the report’s figures, and it suggests the market is entering a steadier growth pha...

Peptide Therapeutics Industry Overview The global peptide therapeutics market size was valued at USD 39.3 billion in 2021 and is expected to expand at a compound annual growth rate (CAGR) of 6.4% from 2022 to 2030.  The rising incidence of cancer as well as metabolic disorders such as osteoporosis, obesity, and diabetes will drive the adoption of peptide therapeutics during the forecast period. Due to the sheer growing number of affected pediatric patients and the pervasiveness of target diseases in low-income countries, there is a high demand for efficient and low-cost drugs. Advanced peptides are now being created and reconfigured as therapeutics for COVID-19. Researchers around the world are looking for compounds that either block the mechanisms involved in Severe acute respiratory infection and replication or treat the conditions resulting from infection. The Food and drug administration updated its description of a biologic on February 21, 2020, to include chemica...